Showing 20 of 72 recruiting trials for “primary-vitreoretinal-large-b-cell-lymphoma”
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
👨⚕️ Huilai Zhang, Tianjin Medical University Cancer Insititute & Hospital📍 1 site📅 Started Jan 2026View details ↗
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
RecruitingNCT07200375 ↗
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Sep 2025View details ↗
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
👨⚕️ Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañón📍 15 sites📅 Started Aug 2025View details ↗
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
👨⚕️ Julie E. Haydu, MD, PhD, Massachusetts General Hospital📍 2 sites📅 Started Jun 2025View details ↗
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
👨⚕️ Farrukh Awan, MD, University of Texas Southwestern Medical Center📍 1 site📅 Started Apr 2025View details ↗
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
👨⚕️ Liang Huang, MD, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Mar 2025View details ↗
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecruitingNCT07198230 ↗
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
👨⚕️ John Kuruvilla, FRCPC, University Health Network, Toronto📍 2 sites📅 Started Jan 2025View details ↗
Page 1 of 4Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →